

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07K 7/08, 7/10, A61K 39/21</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/13564</b> <b>(43) International Publication Date:</b> 15 November 1990 (15.11.90)
<b>(21) International Application Number:</b> PCT/CA90/00146 <b>(22) International Filing Date:</b> 3 May 1990 (03.05.90)  <b>(30) Priority data:</b> 8910145.5                      3 May 1989 (03.05.89)                      GB  <b>(71) Applicant (for all designated States except US):</b> CON- NAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, Willowdale, Ontario M2N 5T8 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> SIA, Dwo, Yuan, Charles [GB/CA]; 27 Mabley Crescent, Thornhill, On- tario L4J 2Z7 (CA). CHONG, Pele [CA/CA]; 20 Bor- rows Street, Thornhill, Ontario L4J 2S4 (CA). KLEIN, Michel [CA/CA]; 16 Munro Boulevard, Willowdale, On- tario M5A 3M2 (CA).		<b>(74) Agent:</b> SIM & McBURNEY; 330 University Avenue, Suite 701, Toronto, Ontario M5G 1R7 (CA).  <b>(81) Designated States:</b> AT (European patent), BE (European + patent), CA, CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European pa- tent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> SYNTHETIC PEPTIDES FOR AN HIV-1 VACCINE  <b>(57) Abstract</b>  The invention discloses the identification, characterisation and use of a synthetic peptide, GPKEPFRDYVDRFYK (p24E), as a T-cell carrier for the appropriate assembly, with defined B-cell epitopes of the HIV-1 envelope protein, for the construction of potential synthetic vaccine candidates against HIV.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

TITLE OF INVENTION  
SYNTHETIC PEPTIDES FOR AN HIV-1 VACCINE

FIELD OF INVENTION

5           The present invention relates to the design and preparation of a synthetic peptide vaccine against acquired immunodeficiency syndrome (AIDS) caused by the human Immunodeficiency Virus (HIV). Particularly, the invention is related to the identification and  
10 characterisation of a T-cell epitope of the core protein, p24, of HIV-1, and methodologies utilising this epitope to construct immunogenic oligopeptides with autologous (p24) and several heterologous (HIV proteins other than p24) B-cell epitopes capable of inducing  
15 effective immunity against HIV.

BACKGROUND OF THE INVENTION

AIDS is the ultimate result of infection with HIV, and there is currently no cure for the disease, so the  
20 development of an HIV-specific vaccine is urgently required. Previously, it has been proven that protective antibodies against a specific disease can be elicited by the administration of specific components of the organism causing the disease, rather than the whole  
25 organism that has been inactivated or has been attenuated to give a non-pathogenic strain. The envelope protein (gp160) of HIV-1 has been employed as a candidate vaccine against AIDS. Although it has been shown that this immunogen, prepared in a vaccinia  
30 vector, is capable of inducing virus neutralising antibodies, all vaccine trials failed to protect primates against challenge with wild HIV isolates. In addition, two regions of the protein gp160, encompassing residues 735-752 and 846-860, respectively, have been  
35 shown to suppress the normal human lymphocyte proliferative response to mitogens in animals immunized with these peptides conjugated to a carrier protein.

This peptide-mediated immunosuppression may play an important role in the pathogenesis of the disease. These results also stress the need for a rational design of any synthetic vaccine against AIDS. To design the best candidate synthetic vaccine, very immunogenic viral B-cell neutralising epitopes (BE) containing a high degree of conserved sequence between viral isolates must be linked to potent T-helper cell determinants (THD) to elicit a strong and long-lasting cross-protective antibody response. Also, HIV-specific cytotoxic T-lymphocyte epitopes (CTL) should be included in the synthetic constructs to provide necessary cell-mediated immunity to HIV disease.

A specific and preferential spatial relationship between certain T- and B-cell epitopes may be necessary for tandem epitopes to be efficiently processed and immunogenic. Thus, it is important to determine whether T- and B-cell epitopes in a proposed designer vaccine are assembled in the optimal configuration so that both T- and B-cell memory can be elicited effectively and antibodies of the desired specificity produced. THD have been found not to be universal and are immunologically functional only when presented in association with the appropriate Major Histocompatibility Complex (MHC) class II antigens. There is a characteristic hierarchy of T-cell epitope dominance. Therefore, to develop a synthetic AIDS vaccine, it is important to identify the most potent THD of the various HIV gp160, gag, pol and other gene products. A number of THD and BE of the gp160 protein have been fully characterised and although the B- and T-epitopes of gag and pol proteins have been predicted by standard algorithms, the structure of these epitopes have yet to be determined experimentally. Recent studies have indicated that the gag gene products may play a crucial role in eliciting an immune response

against HIV infection. Thus, clinical progression of AIDS is associated with a reduction of circulatory antibodies to the gag p24 protein and antibodies raised against an immunodominant gag p17 peptide are capable of inhibiting HIV-1 infection in vitro. Furthermore, Hepatitis B virus core THD have been shown to be more efficient than envelope THD in helping the induction of the antibody response to the S surface antigen. By analogy with the hepatitis B virus system, it was of interest to identify potent gag-THD in HIV. Using conventional structure prediction algorithms for T-cell and B-cell epitopes, we have identified and chemically synthesized a panel of potentially immunogenic gag peptides (Table I) and have extensively studied the immunological properties of one of them, p24E.

#### SUMMARY OF INVENTION

In accordance with one aspect of the present invention, the inventors have found a potent synthetic HIV-1 immunogen (HIV-1 p24) comprising gag-p24 tandem T- and B-cell epitopes. Inbred mouse strains primed with the free HIV-1-p24 peptide in complete Freund's adjuvant, and boosted with the same peptide in incomplete Freund's adjuvant elicited a strong secondary anti-HIV-1 p24 antibody response as judged by a peptide-specific enzyme immunoassay (EIA). The anti-peptide antibodies recognised the viral p24 protein in immunoblotting. In addition, the peptide presented in the appropriate MHC context was shown to be highly stimulatory for p24- specific murine T-cell lines.

The inventors have also demonstrated that the T-cell epitope of HIV-1-p24, p24E, can mediate an antibody response to heterologous B-cell determinants (envelope B-cell determinants, for example) and constructed several immunogenic chimeric p24/gp160 oligopeptides capable of inducing an anti-envelope

antibody response.

The inventors have further shown that polarity of the T- and B-cell epitopes affects the immunogenicity of the chimeric peptides, and that the incorporation of a linker between the two epitopes can modulate the immunogenicity of the peptides.

#### BRIEF DESCRIPTION OF DRAWING

Figure 1 is schematic representation of the structure of the p24E protein.

#### DESCRIPTION OF INVENTION

Two models have recently been proposed for the prediction of T-cell antigenic determinants on the basis of the primary sequence. It has been proposed (ref 1.) that T-cell epitopes are likely to involve protein sequences that have a potential to adopt stable amphipathic  $\alpha$ -helix conformations, such that hydrophilic residues are positioned on one side of the helix and hydrophobic residues lie on the other side. It has been independently observed that a primary sequence pattern occurs frequently in T-cell antigenic sites. This T-cell binding motif usually consists of a charged residue or a glycine followed by two or three hydrophobic residues followed by an hydrophilic residue (ref 2.).

Location of the potential T-cell epitopes of the HIV-I p24 protein has been predicted by structural algorithms (Table 1). The sequence GPKEPFRDYVDRFYK, of one of the predicted p24 T-cell epitopes, p24E, is very highly conserved in the various HIV-1 strains that have been isolated and likely has an amphipathic  $\alpha$ -helix structure as shown in Figure 1.

The results of the in vitro proliferation experiment demonstrating that p24E indeed contains a T-cell epitope are shown in Table 2. The p24-specific

murine T-cell line, Tp241 was found to respond only to the synthetic peptide, p24E, but not to either TE1E or TB8 peptides which individually contain a partial sequence of p24E.

5       The T-cell carrier function of p24E was demonstrated by studying the immunogenicity of an unconjugated oligopeptide HIV-1-p24 encompassing p24E (residues 292-306), and a predicted p24 B-cell epitope, B (residues 307-316), of the gag protein, p24. HIV-1-  
10 P24 and B p24 peptides were injected separately in increasing amounts in complete Freund's adjuvant into five inbred mouse strains of different Major Histocompatibility Complex (MHC) haplotypes. The mice were boosted three weeks later with half the original  
15 amount of peptide in incomplete Freund's adjuvant. Sera were collected 9 days post-challenge and assayed for the presence of peptide-specific IgG antibodies.

Results of the enzyme immunoassay summarised in Table 3 indicate that the free p24 B peptide was not  
20 immunogenic at the three immunising doses (4, 20 and 100 ug) tested. However, this B-cell epitope became immunogenic when linked to the C-terminus of p24E (peptide HIV-1-p24). High titres of anti-HIV-1-p24 IgG were detected in the sera of immunised mice from four  
25 out of the five inbred strains, namely, Balb/c (H-2d), SWR/J (H-2q), C3H (H-2k and C57BL/6 (H-2b). The C57BL/6 and Balb/c mice appeared to be the best responders as judged by their high serum anti-peptide IgG titres (12,000 and 4,000, respectively), while the SWR/J and  
30 C3H strains with anti-HIV-1-p24 titres of 1 in 1,200 and the SJL/J strain with a titre of 1 in 150 were intermediate and poor responders to the peptide, respectively.

The immunogenicity of the B-cell epitope was found  
35 to depend on the polarity of B and p24E peptides. The oligopeptide in which the B-cell epitope, B is linked to

the N-terminus of p24E was unable to induce an antibody response against its B-cell determinant (Table 3).

The specificity of the anti-HIV-1-p24 IgG antibodies was demonstrated by showing that a Balb/c (H-2d) anti-HIV-I-p24 antiserum reacted exclusively against p24 and not against other viral proteins, in EIA's using either recombinant p24 or gp41 (DuPont) or gp160 (Repligen Corp.) as target antigens. The same antiserum also specifically recognized the viral p24 protein in immunoblotting using commercial HIV-1 Western blotting strips (Pan.Data Systems, Bio Rad). These results, therefore, demonstrate that p24E is a potent T-helper epitope (Th) capable of providing "immunological help" to induce the generation of antibody responses against autologous p24 B-cell epitopes in the absence of a foreign carrier protein.

In order to investigate whether the T-helper (Th) epitope, p24E, could also mediate an antibody response against heterologous B-cell determinants, we synthesized a chimeric oligopeptide, p24E-BE3 which contains a non-immunogenic B-cell epitope sequence BE3, encompassing amino acid residues 727 - 751 (LPTPRGPNRPEGIEEEGGDRDRS) of the HIV-1 gp160 envelope protein (ref 3) linked in tandem to the C-terminus of p24E.

The five inbred mouse strains (Balb/c, SJL/J, A/J, C3H and C57BL/6) immunised with the free chimeric peptide following the protocol used for immunisation with the HIV-1-p24 peptide were able to generate a secondary anti-envelope (BE3) antibody response as shown in Table 4. The highest anti-BE3 serum IgG titres (1 in 1,600) were obtained in Balb/c and C57BL/6 mouse strains immunized with 100 ug of p24E-BE3 peptide, suggesting that these two haplotypes are the best responders to the chimeric peptide.

We have introduced a spacer sequence between the T-



and B-cell epitopes to modulate the immunogenicity of a chimeric peptide, BE3-p24E. Unlike in p24E-BE3, the BE3 sequence of the BE3-p24E peptide is located at the N-terminus of p24E. This BE3-p24E peptide was not, immunogenic in the five inbred mouse strains tested (Table 5). In contrast, the chimeric peptide, BE3-PP-p24E in which two proline residues (PP) have been inserted between the T and B-cell epitopes was immunogenic, and able to induce anti-BE3 antibody production in the five inbred mouse strains tested (SJL/J, A/J, C57BL/6, Balb/c and C3H). Collectively, the above results suggest that the enhancement of the immunogenicity of BE3 using p24E as a T-cell carrier is dependent on the polarity of the epitopes. The non-immunogenic form of the synthetic construct, BE3-p24E can be made immunogenic by inserting a linker, such as proline-proline, between the epitopes.

The p24E peptide was also used to enhance the immunogenicity of other heterologous B-cell epitopes. The chimeric peptides, ENV-PP-p24E and p24E-PP-ENV were synthesized using another HIV-1 B-cell epitope, ENV, encompassing the amino acid residues 256-273 (GIRPVVSTQLLNGSLAE) of the envelope protein gp120 (ref 4) linked in tandem to either the N- or C- terminus of p24E, respectively, via a proline-proline linker. The construct p24E-PP-ENV was found to be immunogenic in the five inbred strains examined as judged by the humoral response against the ENV peptide (Table 6). In contrast, ENV-PP-p24E was immunogenic in only three out of the five strains. These results confirm that the polarity of the B- and T- cell epitopes is critical in determining the immunogenicity of chimeric peptides.

The carrier function of the p24E peptide was further assessed by studying the immunogenicity of another chimeric peptide, V3A-PP-p24E. The V3A sequence NTRKSIRIQRGPGRAFTIG (residues 308-327) of the

variable loop of HIV-1 gp 120, Which contains a major neutralising B-cell epitope (ref 5), is not immunogenic in inbred mice (Table 7). The V3A peptide was made immunogenic by being linked to the N-terminus of p24E  
5 via the proline-proline linker. The highest anti-V3A peptide IgG titre was measured in sera of STL/J mice immunised with V3A-PP-p24E.

The invention is further illustrated by the following examples

10

#### EXAMPLES

Methods of peptide synthesis, enzyme immunoassays (EIA) and other immunological testing procedures that are not explicitly described in this disclosure and Examples are amply reported in the scientific literature  
15 and are well within the scope of those skilled in the art.

##### Example I.

This Example illustrates the synthesis of peptides. The oligopeptides shown in Table I were synthesized according to the amino acid sequence reported for the  
20 HIV/LAV isolate using the ABI (Applied Biosystems Inc) 430A peptide synthesizer. The solid-phase synthesis protocol was followed as described by the manufacturer except that addition of histidine was done by double  
25 coupling. The crude peptides were removed from the resin by treatment with hydrofluoric acid in the presence of anisole, thiocresol and dimethyl sulphide followed by precipitation with diethyl ether. The peptides were purified by reverse-phase high performance  
30 liquid chromatography (RP-HPLC) using a Vydac C4 column and an acetonitrile gradient in 0.1% trifluoroacetic acid. Amino acid analyses showed that amino acid compositions of individual purified peptides were correct.

##### 35 Example II.

This Example illustrates the method used to

demonstrate that the p24E peptide is a functional T-cell epitope.

Murine T-cell lines, specific for the peptide HIV1-p24, were generated according to a method similar to that described by Sia (ref 6). An optimal concentration of HIV-1-p24 peptide (100 ug/ml) was used to propagate the antigen-specific Balb/c T-cell lines in the presence of recombinant interleukin-2 (20 u/ml). The ability of the p24E peptide presented by syngeneic splenocytes to induce the proliferation of the T-cell lines in vitro as judged by a standard tritiated thymidine uptake assay clearly demonstrated that p24E contained a functional T-cell epitope (Table 2). In addition, the immunisation of Balb/c mice with the free p24E peptide emulsified in Freund's adjuvant did not elicit an anti-p24E antibody response.

#### Example III.

This Example describes the protocol used to test the immunogenicity of the HIV-1-p24 peptide and chimeric oligopeptides.

Five inbred mouse strains of different MHC haplotypes, namely, Balb/c (H-2d), SJL/J (H-2s), A/J (H-2a), C3H (H-2k) and C57BL/6 (H-2b) were used for immunogenicity studies. Four mice from each strain were immunised with either 4, 20 or 100 ug of the free oligopeptide as follows. The animals received the given dose of the peptide in complete Freund's adjuvant (CFA) by the subcutaneous route; this was followed with a challenge-dose of half of the amount of the same peptide emulsified in incomplete Freund's adjuvant (IFA) three weeks later. Sera of the experimental animals collected on the 9th day post-challenge were assayed for peptide-specific IgG antibodies using a standard EIA.

#### Example IV.

This Example illustrates the testing of anti-peptide antibodies using an Enzyme Immunoassay (EIA).

EIA for the detection of anti-HIV-1-p24 antibodies was performed by coating EIA plates (Maxisorp, NUNC, Denmark) with HIV-1-p24 in phosphate buffered saline (PBS, pH 7.0) at 1 ug per well. Absorption of the peptide was allowed to take place overnight at 4°C. The peptide solution was aspirated from the wells, and the plates were blocked by the addition of 300 ul 2% (w/v) of skimmed milk (Carnation, U.K.) per well. After 2 hr incubation at room temperature, the unbound peptide was removed by washing the plates three times with washing buffer [PBS, pH 7.0, containing 0.025% Tween 20 (Bio-rad Laboratories, Richmond, CA)]. A 3-fold dilution of each of the experimental serum sample starting at 1 in 50 was then made in PBS containing 0.1% skimmed milk, and 100 ul of the diluted serum was then added to each of the peptide-coated wells. Each dilution of serum samples was assayed in duplicate. Binding of the serum anti-HIV-1-p24 antibodies to the immobilized peptide was allowed to take place by incubating the plates for 1 hr at room temperature. The unbound antibodies were removed by washing the plates three times with washing buffer. One hundred ul of goat anti-mouse IgG antibody conjugated to horse-radish peroxidase (Jackson Lab.,) diluted 1 in 5,000 in washing buffer as recommended by the manufacturer, was then added to each wells to detect the specific binding of the anti-HIV-1-p24 IgG to the target peptide. After 1 hr of incubation at room temperature, the unbound antibody-conjugate was removed by washing the plates four times with the washing buffer. The amount of bound conjugate was assayed by the addition of 100 ul of a mixture of tetramethylbenzidine (TMB) and hydrogen peroxide (1 part of TMB to 9 parts of hydrogen peroxide). Colour development was allowed to take place at room temperature in the dark for 10-15 min., and arrested by the addition of 100 ul of 1 N sulphuric acid. The optical densities of the enzyme

reactions were read on a Titertek Multi Skan Spectrophotometer (MCC/340 model) at 450 nm. Results are shown in Table 3 and are expressed as mean reciprocal titres. The reciprocal titres for normal mouse sera, irrespective of the haplotypes, were always <50.

Example V.

This Example further illustrates the detection of anti-HIV envelope peptide antibodies.

Anti-envelope peptide antibodies were detected in an EIA similar to that described above, with the following modifications. EIA plates were coated with streptavidine in PBS at 3ug/well. After the plates were blocked with 2% skimmed milk, 0.1ug of biotinylated envelope peptide (BE3, ENV or V3A) was then added to each of the streptavidine-coated wells. Binding of the biotinylated peptide to streptavidine was allowed to take place for 2 hr. at room temperature. Unbound peptide was removed by washing the plates three times with the washing buffer (PBS, pH 7.0, containing 0.25% Tween 20). Anti-envelope IgG activity was then assayed by adding 100 ul of the experimental sera serially diluted in PBS containing 1% skimmed milk, into each of the wells coated with biotinylated peptide bound to streptavidine. Binding of anti-envelope antibodies was then detected using an affinity-purified goat anti-mouse IgG antibody conjugated to horseradish-peroxidase as described in Example IV. Results were represented in Tables 4, 5, 6 and 7.

Example VI.

This Example illustrates the biotinylation of peptides.

One hundred ul of a solution of NHS-biotin (10 mg NHS-biotin in 1ml dimethylformamide [DMF]) and 0.2 ml of 1M sodium bicarbonate were added to 1 mg of peptide dissolved in 2 ml of either DMF or 6M guanidine

hydrochloride in PBS, pH 7.5. The peptides were allowed to react with NHS-biotin for 2-6 hr at room temperature. After modification, the biotinylated peptides were purified by reverse phase HPLC or gel  
5 filtration chromatography.

Example VII.

This example illustrates the use of the T-cell epitope, p24E as a T-cell carrier peptide.

Immunogenicity studies showed that the five inbred  
10 mouse strains (Balb/c, SJL/J, A/J, C3H and C57BL/6) immunized with the unconjugated chimeric peptide, p24E-BE3, using the protocol as described for the HIV-1-p24 peptide in Example III, were found to be able to generate a secondary anti-envelope peptide (anti-BE3)  
15 antibody response (Table 4).

Example VIII.

This Example illustrates the use of a proline-proline linker to modulate the immunogenicity of chimeric peptides.

20 An immunogenicity experiment similar to that described in Example III was performed with the peptides BE3-p24E and BE3-PP-p24E which contained two proline residues between the T- and B-cell epitopes. Anti-BE3 antibodies were measured by EIA using biotinylated BE3  
25 as the target antigen. Results are represented in Table 5.

Example IX.

This Example illustrates the use of p24E as a T-cell carrier for other heterologous B-cell epitopes.

30 An immunogenicity experiment similar to that in Example III was performed with the chimeric peptides, ENV-PP-p24E, p24E-PP-ENV and V3A-PP-p24E. Results are presented in Tables 6 and 7, respectively.

Example X.

35 This Example illustrates the use of the immunoblotting technique.

Antibodies raised in mice against the synthetic peptides were tested for their immuno-specificity using the immuno-blot technique. HIV-1 viral proteins immobilised on nitrocellulose strips were purchased from

5 Pan Data System Inc. and Bio-rad and immunoblotting was performed according to the manufacturer's specification. Mice sera were assayed at 1 in 100 dilution.

REFERENCES:

1. Delisi and Bersofsky, P.N.A.S., 82, 7048, (1985)
2. Rothbard and Taylor, EMBO, 7, 93, (1988)
3. Kennedy et al., Science, 231, 556, (1986)
- 5 4. Ho et al., Science, 239, 1021, (1988)
5. Matsushita et al., J. Virology, 62(6), 2107, (1988)
6. Sia et al., Immunology, 51, 755, (1984)



TABLE I

Predicted T-Cell Epitopes in the Gag  
Gene Products of HIV-1

<u>Gag Gene Product</u>	<u>Peptide Name</u>	<u>Sequence</u>	<u>Strain Homology</u>
p17	p17A	EELRSLYNTVAT	92%
	p17B	DTKEALDKIEEEQNKSKKKA	80%
p24	p24A	ARTLNAWVKVVEEKAFSPEVIP	85%
	p24B	LKETINEEAAEWDRVHPVHAG	80%
	p24C	GQLREPRGSDIAGTTSTLQEQI	90%
	p24D	IPVGEIYKRWIIILGLNKIVRMYS	80%
	p24E	GPKEPFRDYVDRLFYK	85%
	HIV1-p24	p24E TLRAEQASQEV	80%
	p24F	LEEMMTACQGVGGPGHKARVLAEA	95%
	p24G	TETLLVQNANPDCKTILKALGPAA	85%
p15	p15A	ARNCRAPRKKGCWKCGKEGHQMKDC	80%

TABLE 2

Proliferative response of the Balb/c p24-specific  
T-cell line Tp241 to synthetic HIV peptides

<u>Antigen</u>	<u>Sequence</u>	<u>Proliferation [<sup>3</sup>H-Tdr uptake], counts per minute</u>			
		<u>100 ug</u>	<u>20 ug</u>	<u>4 ug</u>	<u>0.8 ug</u>
p24		17,406±2,412	19,592±2,241	16,875±1,943	6,217±771
p24E (p24)	GPKEFRDYVDRFYK (292-306)	5,216±619	6,274±572	2,612±325	712±81
TE1E (p24)	GPKEFRDY (292-300)	412±47	428±32	311±57	386±41
TB8 (p24)	DRFYKTLR (302-309)	609±79	416±54	363±30	261±24
BE3 (gp160)	LPTPRGPDPRPEGIIEEGGERDRDRS (727-751)	426±48	368±44	264±23	296±25
Control		248±21			
Con A (5ug/ml)		61,727±7,428			

TABLE 3

Comparative immunogenicity studies of the  
HIV-1-p24 and B-24E peptides

Mouse Strain	Haplo- type	Reciprocal anti-HIV-p24 IgG titre					
		Dose					
		4 ug	20 ug	100 ug			
		B	HIV-1-p24E	B-p24E	B	HIV-1-p24E	B-p24E
Balb/c	d	<50	2,000	<50	<50	4,000	<50
SJL/J	s	<50	50	<50	<50	150	50
SWR/J	q	<50	<50	<50	<50	1,200	<50
C3H	k	<50	<50	<50	<50	1,200	50
C57BL/6	b	<50	4,000	<50	<50	12,000	50

TABLE 4Antibody Response to the Peptide p24E-BE3

<u>Reciprocal anti-BE3 peptide IgG titre</u>				
<u>-----Dose-----</u>				
<u>Mouse Strain</u>	<u>Haplotype</u>	<u>4 ug</u>	<u>20 ug</u>	<u>100 ug</u>
Balb/c	d	50	400	1,600
SJL/J	s	< 50	100	100
A/J	a	< 50	<50	400
C3H	k	100	400	400
C57BL/6	b	50	50	1,600

TABLE 5

Studies on chimeric peptides  
BE3-p24E and BE3-PP-p24E

---

<u>Reciprocal anti-BE3 peptide IgG titre</u>						
<u>Mouse Strain</u>	<u>--Anti-BE3-p24E--</u>			<u>--Anti-BE3-PP-p24E--</u>		
	<u>4 ug</u>	<u>20 ug</u>	<u>100 ug</u>	<u>4 ug</u>	<u>20 ug</u>	<u>100 ug</u>
Balb/c	< 50	< 50	< 50 c)	50	50	100
SJL/J	< 50	< 50	< 50	100	100	200
A/J	< 50	< 50	< 50	50	100	400
C3H	< 50	< 50	< 50	200	800	1,600
C57BL/6	< 50	< 50	< 50	< 50	< 50	500

---

TABLE 6

Antibody response to the chimeric  
peptides ENV-PP-24E & p24E-PP-ENV

<u>Reciprocal anti-ENV peptide IgG Titre</u>						
<u>Mouse Strain</u>	<u>--ENV-PP-p24E--</u>			<u>--p24E-PP-ENV--</u>		
	<u>4 ug</u>	<u>20 ug</u>	<u>100 ug</u>	<u>4 ug</u>	<u>20 ug</u>	<u>100 ug</u>
Balb/c	ND	< 50	50 c)	< 50	50	100
SJL/J	ND	50	1,600	< 50	< 50	100
A/J	ND	< 50	< 50	< 50	< 50	800
C3H	ND	< 50	< 50	< 50	100	400
C57BL/6	ND	50	50	400	3,200	3,200

TABLE 7

Immunogenicity of the oligopeptides  
V3A and V3A-PP-P24E

<u>Reciprocal anti-V3A peptide IgG titre</u>				
<u>-----Dose-----</u>				
<u>Mouse Strain</u>	<u>20 ug</u>		<u>100 ug</u>	
	<u>V3A</u>	<u>V3A-PP-p24E</u>	<u>V3A</u>	<u>V3A-PP-p24E</u>
SJL/J	<50	800	<50	800
SWR/J	<50	50	<50	100
A/J	<50	50	<50	50

CLAIMS

1. A synthetic peptide, comprising the amino acid sequence of a T-cell epitope of the gag protein of HIV-1.
2. The peptide of claim 1 wherein the T-cell epitope comprises protein p24E (residues 292 to 306).
3. A synthetic peptide having the amino acid sequence GPKEPFRDYVDRFYK (p24E).
4. A synthetic peptide having the amino acid sequence GPKEPFRDYVDRFYKTLRAEQASQEV (HIV1-p24).
5. A synthetic chimeric peptide comprising the amino acid sequence of a T-cell epitope of the gag protein of HIV-1 linked to the amino acid sequence of a B-cell epitope of an envelope or core protein HIV-1.
6. The peptide of claim 5 wherein the T-cell epitope is p24E (residues 292 to 306) or HIV1-p24.
7. The peptide of claim 6 wherein the B-cell epitope is a B-cell epitope of the core protein linked to the C-terminus of B-cell epitope of the gag protein linked to the C-terminus of the p24E protein.
8. The peptide of claim 6 wherein the B-cell epitope is the BE3 sequence encompassing amino acid residues 727 to 751 of the HIV-1 envelope protein attached to the C-terminus of protein p24E by a linker sequence.
9. The peptide of claim 6 wherein the B-cell epitope is a B-cell epitope linked to the C- or N-terminus of protein p24E by a linker sequence.
10. The peptide of claim 9 wherein the linker sequence is PP.
11. The peptide of claim 10 wherein said B-cell epitope comprises BE3 connected to the N-terminus of protein p24E.
12. The peptide of claim 10 wherein said B-cell epitope comprises the ENV sequence encompassing the acid residue 256 to 273 of the HIV-1 envelope core protein.
13. The peptide of claim 10 wherein the B-cell epitope



comprises the V3A sequence encompassing the amino acid residues 308 to 327 of the variable loop of HIV-1 gp120 protein connected to the N-terminus of protein p24E.

14. A vaccine against HIV-1, comprising, as the component, a synthetic immunogenic protein having the amino acid sequence of a T-cell epitope of the gag protein of HIV-1.

15. The vaccine of claim 14, wherein the T-cell epitope is protein p24E or protein HIV-1-p24.

16. The vaccine of claim 15 wherein the T-cell epitope is linked to a synthetic protein corresponding to a B-cell epitope of a HIV-1 protein.


17. The vaccine of claim 16 wherein the B-cell epitope is the BE3, ENV or V3A protein.

18. The vaccine of claim 17 wherein the B-cell epitope is joined to the C-terminus of the gag protein.

19. The vaccine of claim 17 or 18 wherein the B-cell epitope is joined to the C-terminus by a linker sequence.


20. The vaccine of claim 16, wherein the B-cell epitope is the BE3, ENV or V3A protein joined to the gag protein by a linker sequence comprising PP.

**P24E (GPKEPFRDYVDRFYK)**



# INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 90/00146

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> : C 07 K 7/08, C 07 K 7/10, A 61 K 39/21		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	C 07 K, A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X, Y	EP, A, 0273716 (USA) 6 July 1988 see the whole document; particularly page 10, "Segment 284-309" --	1-5, 14
Y	EP, A, 0290893 (GEN-SYSTEMS) 17 November 1988 see the whole document; particularly page 14, sequence II(147) --	1-5, 14
Y	WO, A, 86/02383 (INST. PASTEUR) 24 April 1986 see pages 0, 22-24, 28-31, 59-60; particular- ly page 59, "Amino-acids 288-331" --	1-5, 14
A	WO, A, 87/02775 (SOUTHWEST FOND. FOR BIOMED. RES.) 7 May 1987 see the whole document --  ./.	1, 5
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
8th August 1990	18. 09. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 H. Ballesteros	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	WO, A, 86/06414 (GEN. SYSTEMS) 6 November 1986 see pages 0-3, 20, 34-50; particularly page 44, claim 23 "IV-(90)" --	1-5, 14
X, Y	EP, A, 0284383 (GEN. SYSTEMS) 28 September 1988 see the whole document; particularly page 6, lines 28-33, "VIII-25-2-6" -----	1-5, 14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9000146

SA 36653

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 05/09/90  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0273716	06-07-88	AU-B- 592258	04-01-90
		AU-A- 1365788	27-07-88
		JP-T- 63503227	24-11-88
		WO-A- 8805051	14-07-88
EP-A- 0290893	17-11-88	AU-A- 1508088	03-11-88
		AU-A- 7720187	19-05-88
		BE-A- 1000811	11-04-89
		DE-A- 3727703	05-05-88
		FR-A- 2603107	26-02-88
		GB-A- 2196634	05-05-88
		JP-A- 1063392	09-03-89
		JP-A- 1085928	30-03-89
		LU-A- 86972	02-03-88
		NL-A- 8701950	16-03-88
		OA-A- 8652	30-11-88
		SE-A- 8703225	21-02-88
WO-A- 8602383	24-04-86	FR-A, B 2571968	25-04-86
		AU-A- 5061785	02-05-86
		EP-A- 0201540	20-11-86
		JP-T- 62500592	12-03-87
		AU-A- 5320086	13-08-86
		WO-A- 8604336	31-07-86
		EP-A, B 0211022	25-02-87
		JP-T- 62502095	20-08-87
		OA-A- 8413	30-06-88
WO-A- 8702775	07-05-87	EP-A- 0245362	19-11-87
		JP-T- 63501716	14-07-88
WO-A- 8606414	06-11-86	US-A- 4629783	16-12-86
		US-A- 4768607	06-09-88
		AU-B- 571128	31-03-88
		AU-A- 5572786	16-10-86
		AU-B- 597884	14-06-90
		AU-A- 5773386	18-11-86
		EP-A- 0201716	20-11-86
		EP-A- 0220273	06-05-87

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9000146

SA 36653

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 05/09/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8606414		JP-T- 62502617	08-10-87
EP-A- 0284383	28-09-88	None	